Shares of Cupid rose nearly 2% to Rs 193 on the BSE on Wednesday after the company said it is on track to report revenue exceeding Rs 150 crore in the first quarter of FY27, which it described as one of the strongest quarterly performances in its history.
Buoyed by the strong start to the financial year and improved visibility across international and domestic markets, the company has also raised its FY27 revenue guidance.
Cupid now expects FY27 revenue of more than Rs 660 crore, up from its earlier guidance of Rs 600 crore, reflecting an upward revision of at least 10%. The company said the revised outlook is backed by its diversified business model, an expanding global opportunity pipeline and increasing operating scale across multiple business verticals.
According to the company, growth is expected to be supported by expanding opportunities in international B2B healthcare markets, driven by demand from institutional buyers, private sector customers and government procurement programmes. It also cited the commencement of its long-term supply agreement with Partnership for Supply Chain Management (PFSCM), Netherlands, which it said strengthens its position in global healthcare procurement.
Cupid said it continues to see strong order visibility across private markets, institutional business and international tenders spanning multiple geographies. It also expects continued growth in its male condom (MC) and female condom (FC) businesses, supported by expanded manufacturing capacity, customer additions and a wider market reach built over the past 12 months.
The company also highlighted growing opportunities in its lubricant portfolio, driven by increasing acceptance across institutional and consumer channels. It said its consumer business offers significant long-term potential as it continues to expand its personal care and wellness brand across modern trade, organised retail and pharmacy networks across Bharat.
Cupid added that ongoing capacity expansion, operational efficiency initiatives and backward integration are expected to support sustained growth while improving profitability. It is also participating in tenders for in vitro diagnostics (IVD) kits and menstrual cups across multiple states.
The company said it continues to make steady progress in its IVD business. While its near-term growth estimates for the segment remain conservative, management believes it has the potential to become a meaningful contributor over the coming years, supported by regulatory approvals, new product launches and continued commercialisation efforts.
Commenting on the performance, Chairman and Managing Director Aditya Kumar Halwasiya said the strong start to FY27 reflects the company's transformation over the past few years and the emergence of multiple growth engines. He said Cupid is witnessing strong momentum in its international B2B business, supported by expanding opportunities in private markets, institutional procurement and government tenders across the world.
